<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861052</url>
  </required_header>
  <id_info>
    <org_study_id>17077</org_study_id>
    <secondary_id>I8F-JE-GPGO</secondary_id>
    <nct_id>NCT03861052</nct_id>
  </id_info>
  <brief_title>A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes</brief_title>
  <acronym>SURPASS J-mono</acronym>
  <official_title>A Phase 3 Study of Tirzepatide Monotherapy Compared to Dulaglutide 0.75 mg in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see if the study drug tirzepatide (LY3298176) is effective
      and safe compared to dulaglutide in participants with type 2 diabetes in Japan.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">April 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 17, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Hemoglobin A1c (HbA1c)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with HbA1c of &lt;7.0%</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants with HbA1c of &lt;7.0%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Serum Glucose</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in fasting serum glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Average 7-Point Self-Monitored Blood Glucose (SMBG) Values</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in average 7-point SMBG values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Body Weight</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in body weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Weight Loss ≥5% from Baseline</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants who achieve weight loss ≥5% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting Insulin</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in fasting insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Fasting C-Peptide</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in fasting C-peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Homeostasis Model Assessment B (HOMA-2B)</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in HOMA-2B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in HOMA-2S</measure>
    <time_frame>Baseline, Week 52</time_frame>
    <description>Change from baseline in HOMA-2S</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Total Hypoglycemia</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Rate of total hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Anti-Tirzepatide Antibodies</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <description>Number of participants with anti-tirzepatide antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">636</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>5 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 milligrams (mg) tirzepatide administered subcutaneously (SC) once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg tirzepatide administered SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg Tirzepatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg tirzepatide administered SC once a week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.75 mg dulaglutide administered SC once a week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirzepatide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>10 mg Tirzepatide</arm_group_label>
    <arm_group_label>15 mg Tirzepatide</arm_group_label>
    <arm_group_label>5 mg Tirzepatide</arm_group_label>
    <other_name>LY3298176</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>0.75 mg Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participant must:

          -  Have been diagnosed with type 2 diabetes mellitus based on the World Health
             Organization classification before the screening visit.

          -  Have HbA1c meeting the following criteria, as determined by the central laboratory at
             screening and baseline:

               -  for participants who are oral antihyperglycemic medication (OAM)-naïve at
                  screening, ≥7.0% to ≤10.0% at both screening and baseline.

               -  for participants who have been taking OAM monotherapy at screening, ≥6.5% to
                  ≤9.0% at screening, and ≥7.0% to ≤10.0% at baseline.

          -  Have body mass index (BMI) of ≥23 kilograms per meter squared at screening.

          -  Be of stable weight (±5%) during 3 months preceding screening; and agree to not
             initiate an intensive diet and/or exercise program during the study with the intent of
             reducing body weight other than the lifestyle and dietary measures for diabetes
             treatment.

        Exclusion Criteria:

        Participant must not:

          -  Have type 1 diabetes mellitus.

          -  Have had chronic or acute pancreatitis any time prior to study entry.

          -  Have proliferative diabetic retinopathy or diabetic maculopathy or nonproliferative
             diabetic retinopathy requiring immediate or urgent treatment.

          -  Have disorders associated with slowed emptying of the stomach, or have had any stomach
             surgeries for the purpose of weight loss.

          -  Have acute or chronic hepatitis, signs and symptoms of any other liver disease, or
             blood alanine transaminase (ALT) enzyme level &gt;3.0 times the upper limit of normal
             (ULN) for the reference range, as determined by the central laboratory. Participants
             with nonalcoholic fatty liver disease (NAFLD) are eligible for participation in this
             trial only if there ALT level is ≤3.0 the ULN for the reference range.

          -  Have had a heart attack, stroke, or hospitalization for congestive heart failure in
             the past 2 months.

          -  Have a personal or family history of medullary thyroid carcinoma or personal history
             of multiple endocrine neoplasia syndrome type 2.

          -  Have been taking weight loss drugs, including over-the-counter medications during the
             last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical corporation THY Tokuyama Clinic</name>
      <address>
        <city>Chiba Mihama-ku</city>
        <state>Chiba</state>
        <zip>261-0004</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akaicho Clinic</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba</state>
        <zip>260 0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kure Medical Center</name>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasegawa Medicine Clinic</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <zip>066-0032</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuri Ono Clinic</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Watanabe Naika Clinic</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>662-0971</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Clinic</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <zip>663-8113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Naka Memorial Clinic</name>
      <address>
        <city>Naka</city>
        <state>Ibaraki</state>
        <zip>311-0113</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hayashi Diabetes Internal Medicine</name>
      <address>
        <city>Chigasaki-sh</city>
        <state>Kanagawa</state>
        <zip>253-0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matoba Diabetes Clinic</name>
      <address>
        <city>Ebina</city>
        <state>Kanagawa</state>
        <zip>243-0432</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kamakura</city>
        <state>Kanagawa</state>
        <zip>247-0056</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Rosai Hospital</name>
      <address>
        <city>Kawasaki</city>
        <state>Kanagawa</state>
        <zip>211-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Minoru Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.E.C. Science Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>235-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OCROM Clinic</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Takatsuki Red Cross Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-1096</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Senrichuo Ekimae Clinic</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asano Clinic</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350 0581</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kawaguchi General Hospital</name>
      <address>
        <city>Kawaguchi</city>
        <state>Saitama</state>
        <zip>332-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakakusa Clinic</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0433</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seiwa Clinic</name>
      <address>
        <city>Adachi-ku</city>
        <state>Tokyo</state>
        <zip>123 0845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meiwa Hospital</name>
      <address>
        <city>Chiyodaku</city>
        <state>Tokyo</state>
        <zip>101 0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HDC Atlas Clinic</name>
      <address>
        <city>Chiyoda</city>
        <state>Tokyo</state>
        <zip>102-0082</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asahi Life Foundation Adult Disease Research Center</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103 0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nihonbashi Sakura Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Center Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>103-0028</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical Trial Centre Fukuwa Clinic</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHL Shinagawa East One Medical Clinic</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>108-0075</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sato Naika Clinic</name>
      <address>
        <city>Ota-ku</city>
        <state>Tokyo</state>
        <zip>143-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tomonaga Clinic</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 0022</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinjuku Research Park Clinic</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>169-0073</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shinei Clinic</name>
      <address>
        <city>Suginami</city>
        <state>Tokyo</state>
        <zip>166-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ikebukuro Metropolitan Clinic</name>
      <address>
        <city>Toshima-ku</city>
        <state>Tokyo</state>
        <zip>171-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Futata Tetsuhiro Clinic</name>
      <address>
        <city>Fukuoka</city>
        <zip>819 0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JR Hiroshima Hospital</name>
      <address>
        <city>Hiroshima</city>
        <zip>732-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yoshimura Clinic</name>
      <address>
        <city>Kumamoto</city>
        <zip>861-8039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keiseikai Kajiyama Clinic</name>
      <address>
        <city>Kyoto</city>
        <zip>6008898</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abe Diabetes Clinic</name>
      <address>
        <city>Oita</city>
        <zip>870-0039</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OKAYAMA Medical Center</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC nishi-umeda clinic</name>
      <address>
        <city>Osaka</city>
        <zip>530-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitada Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>538 0044</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanko Clinic</name>
      <address>
        <city>Osaka</city>
        <zip>559 0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suruga Clinic</name>
      <address>
        <city>Shizuoka</city>
        <zip>424-0855</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 15, 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>April 21, 2020</last_update_submitted>
  <last_update_submitted_qc>April 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
    <mesh_term>LY3298176</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://www.clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

